BGLC Stock Tumbled Over 13% Today: Why Is VitaGuard Commercialization Agreement Drawing Investor Attention?

BioNexus Gene Lab Corp. (BGLC) announced on Wednesday that it has entered into definitive agreements with Asia-based firms Fidelion Diagnostics Pte. and Tongshu Biotechnology, among other parties, to commercialize VitaGuard in Southeast Asia.

VitaGuard is a high-fidelity, tumor-naïve liquid-biopsy platform for minimal residual disease. Minimal residual disease (MRD) is a small number of cancer cells that remain in the body during or after treatment, which are undetectable by standard methods.

China-headquartered Tongshu Gene is the original developer of the VitaGuard technology. The firm is the manufacturing partner of Singapore-based Fidelion. The partnership aims to support the planned commercialization of MRD testing in Southeast Asia. 

Get updates to this developing story directly on Stocktwits.

Share

·

Add us on